ReviewJournal of nephrology2015
Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool.
Review in Journal of nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology.Journal of nephrology · 2020Guideline
- Education and cooking methods in the management of calcium and PTH serum levels in patients on hemodialysis: a randomized controlled study.Journal of nephrology · 2024Trial
- Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial.Journal of the American Society of Nephrology : JASN · 2019Trial
- Disaster emergency meal plans for Korean patients who require hemodialysis.Kidney research and clinical practice · 2025Article
- Nutritional intervention in end-stage renal disease: a clinical trial study.Frontiers in nutrition · 2024Article
- Reduced phosphorus is associated with older age and hypoalbuminemia. Risk factors for all-cause mortality in peritoneal dialysis patients.Frontiers in nutrition · 2023Article
- The Impact of Chronic Kidney Disease on Nutritional Status and Its Possible Relation with Oral Diseases.Nutrients · 2022Review
- Identifying a minimum data set as a necessity to design a web-based personal health record for patients under chronic dialysis.Journal of family medicine and primary care · 2022Article
- 1,25-dihydroxyvitamin D as Predictor of Renal Worsening Function in Chronic Kidney Disease. Results From the PASCaL-1,25D Study.Frontiers in medicine · 2022Article
- Phosphate binders in dialysis: better satisfied than sorry.Clinical kidney journal · 2021Article
- Do we need new phosphate binders in dialysis?Clinical kidney journal · 2021Article
- COVID-19 in Chronic Kidney Disease: The Impact of Old and Novel Cardiovascular Risk Factors.Blood purification · 2021Review
- Relationship between serum phosphate levels and survival in chronic hemodialysis patients: interactions with age, malnutrition and inflammation.Clinical kidney journal · 2021Article
- Phosphate clearance in peritoneal dialysis.Scientific reports · 2020Observational
- Phosphates in medications: Impact on dialysis patients .Clinical nephrology · 2020Article
- Therapeutic Effect of Iron Citrate in Blocking Calcium Deposition in High Pi-Calcified VSMC: Role of Autophagy and Apoptosis.International journal of molecular sciences · 2019Article
- Management of Secondary Hyperparathyroidism in Chronic Kidney Disease: A Focus on the Elderly.Drugs & aging · 2019Review
- Higher Intra-Dialysis Serum Phosphorus Reduction Ratio as a Predictor of Mortality in Patients on Long-Term Hemodialysis.Medical science monitor : international medical journal of experimental and clinical research · 2019Observational
- Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide.American journal of nephrology · 2018Article
- Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.Therapeutics and clinical risk management · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phosphate metabolism is crucial in the pathophysiology of secondary hyperparathyroidism and vascular calcification. High phosphate levels have been consistently associated with unfavorable outcomes in dialysis patients, but several limitations are still hampering a resolutive definition of the optimal targets of phosphate serum levels to be achieved in this cohort. Nonetheless, hyperphosphatemia is a late marker of phosphate overload in humans. Clinical nephrologists routinely counteract the positive phosphate balance in dialysis patients through nutritional counseling, stronger phosphate removal by dialysis and prescription of phosphate binders. However, the superiority against placebo of phosphate control by diet, dialysis or binders in terms of survival has never been tested in dedicated randomized controlled trials. The present review discusses this conundrum with particular emphasis on the rationale supporting the value of a simultaneous intervention against phosphate overload in dialysis patients via the improvement of dietary intakes, dialysis efficiency and an individualized choice of phosphate binders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.